Español
United States
Providers Newsletter
Where Cardiovascular Prevention and Therapies Are Heading in 2026
June 11, 2026
Estimated Reading Time: 4m
Getty Images
Every biological function depends, directly or indirectly, on the heart functioning properly. If your electrical impulses short‑circuit, this can trigger a domino effect of ailments, according to medical literature.
That's why it's essential to maintain cardiac conduction—the process by which electrical impulses are generated and transmitted through the heart muscle—at a healthy balance. This network of specialized cells dictates the rhythm and coordinates the contractions of the heart chambers (atria and ventricles), allowing the efficient pumping of blood throughout the body. Experts gathered at the most recent academic meeting on this specialty, Heart Rhythm 2026, which took place in Chicago in April, presented the latest technological advances in this field.
Knowledge about the past, the genetic heritage we carry that predisposes us or not to certain conditions, together with current technology, achieves a powerful combination to maximize the word “prevention” and the phrase “early detection”, which were the main topics of discussion.
Key developments in early diagnosis
- Continuous monitoring and wearables. Advances in consumer devices allow for long‑term monitoring of heart rate. Modern smartwatches use algorithms that combine ECG sensors and photoplethysmography (PPG) to detect atrial fibrillation episodes and heart blocks on an outpatient basis and in real time. This is a technology that evolves every day.
- Advanced cardiac imaging. Efforts have intensified to standardize the integration of artificial intelligence in echocardiograms and cardiac magnetic resonance imaging (4D). This allows specialists to identify incipient mechanical alterations or microscopic scars associated with cardiomyopathies that cause conduction disorders.
- Integration of biomarkers and genetics. Screening for hereditary predispositions to conduction syndromes and transthyretin amyloid cardiomyopathy (ATTR) now includes new blood tests and genetic panels that identify inflammation or cardiac stress prior to the manifestation of any visible symptoms.
One of the presentations that generated the most anticipation during the Heart Rhythm 2026 congress was the LEAP2 trial, which evaluates a novel leadless pacemaker designed for stimulation of the conduction system. This first‑in‑human study involved 19 patients.
The device is implanted through the internal jugular vein using a deflectable sheath that is positioned across the tricuspid valve.
Although promising, the test also revealed a major mechanical problem. Three cases of device displacement occurred during the follow‑up period: two were detected before hospital discharge and one occurred within the first month after implantation.
In all cases, the devices were removed and replaced with conventional leadless pacemakers. The researchers explained that this problem could be corrected by redesigning the anchoring system to prevent the device from unscrewing from the myocardium.
Emerging PFA technologies
There are three emerging pulsed field ablation (PFA) technologies aimed at improving lesion durability, procedure efficiency, and visualization during atrial fibrillation ablation.
One of the studies evaluated the Faraflex PFA focal catheter from Boston Scientific, a nine‑millimeter basket‑shaped device used for pulmonary vein isolation (PVI) and to create additional linear lesions. The study, conducted in three European centers, included 105 patients.
The favorable results prompted the launch of a pivotal trial in the United States, scheduled to begin this year, while the study is currently in the participant recruitment phase.
A second study, the Vision AF trial, evaluated the OptiShot balloon‑based PFA catheter from CardioFocus, which incorporates an integrated endoscope to allow doctors to directly visualize contact with the tissue during ablation.
The study, conducted on 50 patients, showed high durability: the final ablation strategy achieved a 100% maintenance rate of pulmonary vein isolation during remapping procedures. Furthermore, the six‑month follow‑up revealed an arrhythmia‑free survival rate of close to 90%.
The third study analyzed the nanosecond pulsed field ablation (nsPFA) system of Pulse Biosciences within the framework of the US study NANOPULSE‑AF. This system is designed to deliver shorter energy pulses compared to conventional systems, which operate in the microsecond range.
The principle behind nanosecond technology is that compressing the waveform allows for the delivery of higher voltages while minimizing heating in the near field. This could help to streamline procedures without compromising security.
The first human study included 177 patients in three European centers and demonstrated a durability of over 90% in the isolation of the pulmonary veins, in addition to the ability to generate linear lesions and lesions on the posterior wall of the heart.
Another critical point discussed at the meeting was:
- Standardization of Risk Guidelines:Current guidelines published by the American Heart Association emphasize lifelong cardiovascular risk assessment, enabling cardiologists and primary care physicians to more accurately predict and prevent the development of intraventricular blocks and life‑threatening arrhythmias.
LINKS
https://www.heartrhythmjournal.com/article/S1547‑5271(26)02263‑0/fulltext
https://cardiovascularbusiness.com/topics/cardiac‑imaging/ep‑lab/exploring‑latest‑data‑pfa‑and‑leadless‑conduction‑system‑pacing
https://heart.bmj.com/content/early/2026/05/13/heartjnl‑2025‑326980.info
https://newsroom.heart.org/news/nuevo‑estudio‑que‑explora‑como‑mejorar‑el‑diagnostico‑de‑una‑afeccion‑cardiaca‑a‑menudo‑pasada‑por‑alto
Rhythm Society’s (HRS) Annual Scientific Sessions took place in Chicago, IL, from April 23–26, 2026.
https://clinicaltrials.gov/study/NCT06510556
https://investors.pulsebiosciences.com/news‑releases/news‑release‑details/pulse‑biosciences‑enrolls‑first‑patients‑nanopulse‑af‑ide
Pivot Health Data Breach
Click here for information.
illumifin Data Breach
Click here for information regarding the data breach involving our third‑party administrator, illumifin.